TP 53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are
among the most lethal malignancies, characterized by dismal outcomes with currently …

Improved understanding of TP53 biology and the clinicopathological features of TP53-
mutated myeloid neoplasms has led to the recognition of TP53-mutated acute myeloid …

Clonal cytopenia of undetermined significance (CCUS) is defined by a myeloid driver
mutation in the context of otherwise unexplained cytopenia. CCUS has an inherent risk of …

Abstract Therapy-related Myeloid Neoplasm (t-MN) represents one of the worst long-term
consequences of cytotoxic therapy for primary tumors and autoimmune disease. Poor …

Therapy-related myeloid neoplasms (t-MN) are aggressive myeloid neoplasms. Factors
predicting post-allogeneic stem cell transplant (alloSCT) survival are not well-known. We …

TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally
associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of …

Therapy-related myeloid neoplasms (t-MN) are characterized by aggressive features and a
dismal prognosis. Recent evidence suggests a higher incidence of t-MN in individuals …

Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior
exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long …

Current therapies for high-grade TP53-mutated myeloid neoplasms (≥ 10% blasts) do not
offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority …

Simple Summary Myelodysplastic syndrome (MDS) is one of the most-common blood
cancers in older individuals. Although azacitidine is the most-commonly used treatment for …